000132452 001__ 132452
000132452 005__ 20240229105016.0
000132452 0247_ $$2doi$$a10.2147/CLEP.S145636
000132452 0247_ $$2pmid$$apmid:29403313
000132452 0247_ $$2pmc$$apmc:PMC5783152
000132452 0247_ $$2altmetric$$aaltmetric:32780795
000132452 037__ $$aDKFZ-2018-00140
000132452 041__ $$aeng
000132452 082__ $$a610
000132452 1001_ $$0P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aWeigl, Korbinian$$b0$$eFirst author$$udkfz
000132452 245__ $$aStrongly enhanced colorectal cancer risk stratification by combining family history and genetic risk score.
000132452 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2018
000132452 3367_ $$2DRIVER$$aarticle
000132452 3367_ $$2DataCite$$aOutput Types/Journal article
000132452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660208325_22214
000132452 3367_ $$2BibTeX$$aARTICLE
000132452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132452 3367_ $$00$$2EndNote$$aJournal Article
000132452 520__ $$aFamily history (FH) and genetic risk scores (GRSs) are increasingly used for risk stratification for colorectal cancer (CRC) screening. However, they were mostly considered alternatively rather than jointly. The aim of this study was to assess the potential of individual and joint risk stratification for CRC by FH and GRS.A GRS was built based on the number of risk alleles in 53 previously identified single-nucleotide polymorphisms among 2,363 patients with a first diagnosis of CRC and 2,198 controls in DACHS [colorectal cancer: chances for prevention through screening], a population-based case-control study in Germany. Associations between GRS and FH with CRC risk were quantified by multiple logistic regression.A total of 316 cases (13.4%) and 214 controls (9.7%) had a first-degree relative (FDR) with CRC (adjusted odds ratio [aOR] 1.86, 95% CI 1.52-2.29). A GRS in the highest decile was associated with a 3.0-fold increased risk of CRC (aOR 3.00, 95% CI 2.24-4.02) compared with the lowest decile. This association was tentatively more pronounced in older age groups. FH and GRS were essentially unrelated, and their joint consideration provided more accurate risk stratification than risk stratification based on each of the variables individually. For example, risk was 6.1-fold increased in the presence of both FH in a FDR and a GRS in the highest decile (aOR 6.14, 95% CI 3.47-10.84) compared to persons without FH and a GRS in the lowest decile.Both FH and the so far identified genetic variants carry essentially independent risk information and in combination provide great potential for CRC risk stratification.
000132452 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132452 588__ $$aDataset connected to CrossRef, PubMed,
000132452 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b1$$udkfz
000132452 7001_ $$aKnebel, Phillip$$b2
000132452 7001_ $$aHsu, Li$$b3
000132452 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000132452 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000132452 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S145636$$gVol. 10, p. 143 - 152$$p143 - 152$$tClinical epidemiology$$v10$$x1179-1349$$y2018
000132452 909CO $$ooai:inrepo02.dkfz.de:132452$$pVDB
000132452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132452 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132452 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132452 9141_ $$y2018
000132452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132452 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132452 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132452 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132452 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000132452 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x2
000132452 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000132452 980__ $$ajournal
000132452 980__ $$aVDB
000132452 980__ $$aI:(DE-He78)C070-20160331
000132452 980__ $$aI:(DE-He78)C020-20160331
000132452 980__ $$aI:(DE-He78)G110-20160331
000132452 980__ $$aI:(DE-He78)L101-20160331
000132452 980__ $$aUNRESTRICTED